PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18821609-3	2008	Disease severity of CTD was assessed in terms of diffusing capacity for carbon monoxide (%DL(CO)) and estimated systolic pulmonary arterial pressure (sPAP), and progression of PAH in terms of pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR).	Carbon Monoxide	72-87	CTD	Homo sapiens	20-23	
34065585-7	2021	Results: CTD-PAH patients had higher levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and lower predicted diffusing capacity of carbon monoxide (DLCO) than iPAH patients.	Carbon Monoxide	142-157	CTD	Homo sapiens	9-12	
18383374-11	2008	Moreover, unlike in IPAH, a linear relationship between the FCSA/BSA and the diffusing capacity for carbon monoxide (DLCO) was observed in PAH-CTD (r=0.54, P<0.03).	Carbon Monoxide	100-115	CTD	Homo sapiens	143-146	
33823923-8	2021	Patients with CTD-CPFE had a higher frequency of pulmonary hypertension and pulmonary fibrosis > 20% of the total lung volume, higher ratio of the forced vital capacity to the diffusion capacity of the lung for carbon monoxide (DLCO), lower arterial oxygen pressure at rest, and lower DLCO compared to those in patients with CTD-ILD without emphysema.	Carbon Monoxide	211-226	CTD	Homo sapiens	14-17	
12435296-1	2002	OBJECTIVE: To evaluate the value of diffusing capacity of carbon monoxide (CO) as a sensitive and effective test for the diagnosis of early interstitial lung disease (ILD) associated with connective tissue disease (CTD).	Carbon Monoxide	58-73	CTD	Homo sapiens	215-218	
12435296-1	2002	OBJECTIVE: To evaluate the value of diffusing capacity of carbon monoxide (CO) as a sensitive and effective test for the diagnosis of early interstitial lung disease (ILD) associated with connective tissue disease (CTD).	Carbon Monoxide	75-77	CTD	Homo sapiens	215-218	
34350280-6	2021	At baseline, CTD-PAH patients had lower diffusing capacity for carbon monoxide and lower haemoglobin but, at the same time, lower N-terminal prohormone-brain natriuretic peptide, longer 6 min walk distance, better haemodynamics and more often a low-risk profile.	Carbon Monoxide	63-78	CTD	Homo sapiens	13-16	
29607151-8	2018	CTD-ILD with LC was more likely in patients who were older, male, and smokers; had rheumatoid arthritis, a usual interstitial pneumonia pattern, emphysema on chest computed tomography scan, and lower diffusing capacity of the lung carbon monoxide (DLco)% predicted; and were not receiving immunosuppressive therapy.	Carbon Monoxide	231-246	CTD	Homo sapiens	0-3	
31694110-7	2019	Logistic regression analysis revealed that elevated KL-6 and decreased Carbon monoxide diffusion capacity were independently correlated with the occurrence of CTD-ILD, the decreased of DLcoSB% (OR=0.928, 95%CI: 0.891-0.968) and increase of KL-6 level (OR=1.005, 95%CI: 1.003-1.007) was the independent risk factor for the occurrence of ILD.	Carbon Monoxide	71-86	CTD	Homo sapiens	159-162